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Change in tumor volume after chemotherapy appears to
have a prognostic significance for the outcome of osteo-
sarcoma. A newly developed volume measurement method
based on three-dimensional summation with a proved repro-
ducibility was utilized to measure osteosarcoma tumor volume.
This retrospective analysis included 38 patients with biopsy-
proven, nonsurface, skeletal high-grade osteosarcoma. The
treatment was started by using three cycles of preoperative
chemotherapy with cisplastin (100 mg/m
2) and adriamycin (30
mg/m
2). The tumor volume was measured before and after
preoperative chemotherapy using three-dimensional magnetic
resonance image measurement. The percentage of tumor
necrosis was assessed by pathologic exam. After three cycle
of postoperative chemotherapy, the patients were followed up
at regular interval. For the 23 good responder patients, the
mean survival time was 73.2 months (95% confidence interval
61.9 - 84.5 months), and for the 15 poor responder patients,
the mean survival time was 50.8 months (95% confidence
interval 38.6 - 63.1 months) (p<0.05). For the 14 patients with
increased tumor volume after chemotherapy, the mean survival
time was 47.5 months (range: 36.3 - 58.6 months) and for the
24 patients with stable or decreased tumor volume, the mean
survival time was 74.3 months (range: 63.79 - 84.88 months)
(p<0.05). Among the various factors, histopathologic response
and tumor volume change after chemotherapy predicted dis-
ease free survival (p<0.05). Change in the tumor volume that
was measured with a reproducible method and the histo-
pathologic response after chemotherapy were the important
predictors of disease free survival for osteosarcoma patients.
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INTRODUCTION
With the introduction of aggressive chemo-
therapy for high-grade osteosarcoma, the long
term survival rate for patients with localized
osteosarcoma has dramatically improved.
1 The
metastasis free survival rate after systemic chemo-
therapy has risen to 60% to 70% compared with
10% to 15% after local treatment alone
2-4 Preo-
perative and postoperative chemotherapy in com-
bination with limb salvage surgery often offers ac-
ceptable functional results and survival.
5 Among
the numerous prognostic factors,
6-12 the histologi-
cal response of tumor to preoperative chemo-
therapy is the most important predictor of disease
free survival.
1,10 Therefore, it is important to deter-
mine whether the tumor truly has had a response
to chemotherapy during the courses of preopera-
tive chemotherapy. Knowing the susceptibility of
tumor to preoperative chemotherapy renders
valuable information to the physician for selecting
the proper options for definitive surgery and the
postoperative chemotherapeutic regimens. How-
ever, it is still impossible to determine the respon-
siveness of tumor to preoperative chemotherapy
without a resected specimen because the respon-
siveness of tumor is currently determined by as-
sessment of the histological response of the re-
sected specimens.
13 Hence, many researchers have
tried to elucidate correlation of the tumor volume
change with the histopathological response after
chemotherapy.
6,13 There have been problems with
previous studies including the simple assumption
that the maximal length of tumor represents
tumor volume, calculation of tumor volume by
using an ellipsoid formula and calculation of
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volume without any acceptable reproducibility.
Therefore, a more accurate method has been
deemed necessary to determine the exact mea-
surement of tumor volume. Accordingly, the
authors have tested the feasibility of volumetric
measurement of osteosarcoma volume with a
three dimensional summation method from mag-
netic resonance imaging, and then we proved that
tumor volume change after chemotherapy was
well correlated with the histopathological re-
sponse along with having an acceptable repro-
ducibility of our measurement method.
14 With a
solid correlation between the histopathological
response and tumor volume change after chemo-
therapy, the survival analysis of patients with
osteosarcoma is mandatory to prove an indepen-
dent effect of tumor volume change after chemo-
therapy for the disease free survival rate. There-
fore, the objectives of the current study was to test
the prognostic significance of the actual tumor
volume change after chemotherapy for the disease
free survival rate of patients with osteosarcoma.
MATERIALS AND METHODS
This retrospective analysis included 38 patients
with biopsy-proven, nonsurface, skeletal high-
grade osteosarcoma, and these patients were fol-
lowed up for an average of 48 months (range: 5
to 80 months). At the start of this study, 41
patients were enrolled, however, 3 patients were
excluded due to their failure to maintain follow
up after definitive surgery. The tumors were
located in the distal femur in 15 patients, in the
proximal tibia in 10 patients, in the proximal
humerus in 10 patients, and in other locations
including the proximal femur, middle femur and
distal tibia in 3 patients. The histologic subtypes
of the tumors were osteoblastic osteosarcoma in
34 patients and chondroblastic osteosarcoma in 4
patients. The baseline investigation included plain
radiography and magnetic resonance imaging
(MRI) of the primary bone lesion for the initial
staging and measurement of the pretreatment tu-
mor volume. MRI studies were performed on 1.5
Telsta superconducting systems (General Electrics
Horizon, Milwaukee, WI; Siemens Vision, Munich,
Germany). Magnetic resonance images were ac-
quired in the axial, sagittal, and coronal planes
using T1 weighted (TR/TE: 300 - 700 ms/10 - 20
ms), and T2 weighted (TR/TE: 2000 - 3500 ms/60 -
990 ms) conditions. In addition, T1 weighted (TR/
TE: 300 - 700 ms/12 - 20 ms) gadolinium diethy-
lene triamine penta-acetic acid enhanced spin
echo sequences were also obtained. A 15 to 30 cm
field of view was used, and the matrix size was
256 × 256. Metastatic tumors were screened by
plain chest radiograph, radionuclide bone scan
and computed tomography (CT) of the chest.
Staging was done according to the surgical stag-
ing system of the Musculoskeletal Tumor So-
ciety.
15 In this system, high-grade intracompart-
mental lesion were staged as IIA, and a high-
grade lesion with extracompartmental extension
were staged as IIB. Stage IA, IB and III lesions
were excluded from the study. There were three
cases of stage IIA osteosarcoma and the remaining
cases were stage IIB osteosarcoma. The treatment
started using three cycles of preoperative chemo-
therapy with an intraarterial infusion of cisplastin
(100 mg/m
2) and an intravenous administration of
doxorubicin (30 mg/m
2). Follow-up radiographs
and MRI of the tumors were taken to assess the
tumor volume change. After definitive surgeries
including resection and prosthetic replacement,
resection with arthrodesis and amputation, three
cycles of postoperative chemotherapy were then
done. To detect the development of metastatic le-
sions during the follow-up periods, chest radio-
graph and CT of the chest were performed at
regular intervals.
All images of MRI were scanned, digitized and
transferred to MatLab program (MatLab, Mat
Work Inc, Natick, MA, USA) using a special file
conversion. The absolute tumor volume (cm
3) was
calculated by the summation of each tumor area
multiplied by the slice thickness using three-di-
mensional summation software (MatLab) after
employing a scale correction as described previ-
ously.
14 The total tumor volume was calculated
from the outermost boundaries of the tumor.
Intraosseous tumor volume was calculated from
the tumor that was inside the interrupted cortical
envelope. Extraosseous tumor volume was calcu-
lated by subtracting the intraosseous volume from
the total tumor volume. Relative tumor volumes
were defined as absolute volumes divided byTumor Volume Change after Chemotheraphy as a Predictive Factor of Disease Free Survival for Osteosarcoma 121
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body surface area 16 to normalize for each
patient's stature.
16 Tumor volume change was de-
fined as the difference in tumor volume between
the preoperative chemotherapy and the post-
operative chemotherapy.
After surgical resection of the tumor, the speci-
men was cut into slices. The percentage of histolo-
gically viable tumor was scored as previously
described.
17 If the percentage of necrosis was less
than 90% (Huvos Grades I and II), the patient was
considered to be a poor responder. If more than
90% of necrosis was found (Huvos Grades III and
IV), the patient was regarded as a good respon-
der. In this study, 25 patients were good respon-
ders and 13 patients were poor responders.
As reported previously,
14 the percent coeffi-
ciency of variation (CV) for the intra-observer var-
iability ranged from 1.2 - 3.8%, and for the inter-
observer variability ranged from 1.4 - 4.5% for the
T1WIs, T2WIs, and GdEIs. Based on these ranges
of measurement variability, the significant tumor
volume change was defined as more than 4.5%
changes in the volume compared with the pre-
treatment tumor volume. Therefore, patients with
a change in tumor volume within 4.5% of the pre-
operative volume were grouped together as hav-
ing stable tumor volume. Patients with increases
or decreases in tumor volume of more than 4.5%
of the preoperative volume were grouped to-
gether as having increased tumor volume or
decreased tumor volume, respectively.
All data were analyzed and tested using statis-
tical software SPSS (SPSS Inc, Chicago, IL, USA).
The correlation of the volume changes with the
histopathologic response were analyzed using
Pearson's correlation analysis. The tumor volume
changes between the good and poor responders
were evaluated by the Mann-Whitney test. Kaplan-
Meyer survival analysis with log rank statistics
and Cox regression analysis as a multivariate an-
alysis were also performed. Failures were defined
by the occurrence of metastasis, local recurrence
and tumor related death. P value below 0.05 was
considered statistically significant.
RESULTS
Among the 38 patients who were available for
follow-up, fourteen patients developed pulmo-
nary metastases or local recurrences. Of the 14
patients with recurrence or metastasis, only seven
patients were still alive at the end of their follow-
up period. In the good responder group, six
patients out of 25 developed metastases or recur-
rences. In the poor responder group, eight
patients out of 13 showed metastases or recur-
rences. In the good responder group, four patients
(16%) out of 25 actually showed an increased tu-
mor volume, while in the poor responder group,
ten patients (77%) out of 13 actually showed an
increased tumor volume after chemotherapy.
For patients having increased tumor volume,
nine patients (64%) out of 14 patients developed
metastases or recurrence. For patients having
stable or decreased tumor volume, five patients
(21%) out of 24 patients showed metastases or
recurrences.
Using the Kaplan Meyer's method, the esti-
mated mean disease free survival rates were
calculated. For the 25 good responder patients, the
mean survival time was 73.2 months (95% con-
fidence interval 61.9 - 84.5 months), and for the 13
poor responder patients, the mean survival time
was 50.8 months (95% confidence interval 38.6 -
63.1 months) (p<0.05) (Fig. 1).
For the 14 patients having increased tumor
Fig. 1. Kaplan-Meier analysis for disease free survival of
the good histopathologic responder group vs. the poor
histopathologic responder group. Failure was defined as
local recurrence, distant metastasis and tumor related
death. Good responders showed a mean survival of 73.2
months (95% confidence interval 61.9 - 84.5 months), and
the poor responder showed a mean survival of 50.8
months (95% confidence interval 38.6 - 63.1 months). *p<
0.05.Seong-Hwan Moon, et al. 122
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volume after chemotherapy, their mean disease
free survival was 47.5 months (95% confidence
interval 36.3 - 58.6 months) and for the 24 patients
with stable or decreased tumor volumes, their
mean disease survival was 74.3 months (95% con-
fidence interval 63.7 - 84.8 months) (p<0.05) (Fig.
2). Cox regression analysis as a multivariate an-
alysis was performed to test the significance of
each factor in predicting disease free survival.
Among the various factors including gender, age,
histologic type, location of tumor, type of limb
salvage surgery, histopathologic response after
chemotherapy and tumor volume change after
chemotherapy, only the histopathologic response
and tumor volume change after chemotherapy
predicted disease free survival (p<0.05).
DISCUSSION
This retrospective study on tumor volume
change investigated the prognostic significance of
volume change on the disease free survival in
osteosarcoma, and the study provide clinically
relevant information in regards to decision
making during the course of preoperative chemo-
therapy. In this study, the actual tumor volume
change after preoperative chemotherapy proved
to be not only correlated with the histopathologic
response, but it also predicted the disease free
survival.
Several reports have dealt with the significance
of tumor size on the prognosis.
1,3,6-8 Nevertheless,
most of these previous studies utilized relative
measurements of tumor volume that were really
just an easily available approximation of volume.
In the past, tumor volume has been measured
using the ellipsoid mass formula with the visible
dimensions from plain radiographs and MRI,
6,13,
17-19 or with the single largest diameter of a
resected specimen 8 with the few exceptions being
the studies that used direct three-dimensional
volume measurement by CT
20 and MRI.
21 Tumor
volume may be more accurately measured using
a three-dimensional technique, since tumors tend
to have an irregular shape that does not fit well
into the ellipsoid formula. Although a three-di-
mensional volumetric method with MRI was
applied for tumor volume measurement in a
previous report,
21 the study had the following
shortcomings: a small number of patients, the lack
of a reproducible analysis of their measurement
methods, and there was no data for comparison
between the histopathologic response and volume
change. In contrast to the previous reports, the
authors of this study developed a method to mea-
sure the actual tumor volume using T2 weighted
MRI images with a proven acceptable reproduci-
bility.
14 In this current study, the long term dis-
ease free survival was plotted according to the
histopathologic response and actual tumor vol-
ume change after preoperative chemotherapy.
Tumor volume increase, as defined by a 4.5%
increase compared to the prechemotherapy tumor
volume, independently affected the disease free
survival in an adverse fashion. Furthermore,
among the various prognostic factors, only the
tumor volume change and histopathologic re-
sponse after preoperative chemotherapy provided
for independent prediction of disease free survival
for patients with osteosarcoma. Therefore, the
authors recommend that the actual tumor volume
change be used as an indicator for predicting the
histopathologic response and disease free survi-
val, and also these parameters can be used as
clinical guidelines for selecting the definitive
Fig. 2. Kaplan-Meier analysis for disease free survival of
the stable or decreased tumor volume group vs. the
increased tumor volume group. Failure was defined as
local recurrence, distant metastasis and tumor related
death. The stable or decreased tumor volume group
showed a mean survival of 74.3 months (95% confidence
interval 63.7 - 84.8 months), and the increased tumor
volume group showed a mean survival of 47.5 months
(95% confidence interval 36.3 - 58.6 months). *p<0.05.Tumor Volume Change after Chemotheraphy as a Predictive Factor of Disease Free Survival for Osteosarcoma 123
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surgical options.
The limitation of this study was our inability to
differentiate viable tumor tissue from necrotic,
hemorrhagic tissue and inflammation when calcu-
lating tumor volume. The total tumor volume was
measured, which included viable tumor, necrosis,
hemorrhage and inflammation without consid-
ering tumor viability. In the future, studies con-
cerning the dynamic imaging of osteosarcoma
combined with the exact volumetric measurement
of specific areas will be necessary.
In this study, change in the tumor volume after
preoperative chemotherapy was measured with
reproducible three-dimensional magnetic reso-
nance imaging, and disease free survival was
analyzed with various factors including gender,
age, histologic type, location of tumor, type of
limb salvage surgery, histopathologic response
after chemotherapy and tumor volume change
after chemotherapy. The histopathologic response
and change in tumor volume after chemotherapy
represent the statistically independent predictors
of disease free survival.
In conclusion, the change in tumor volume, as
measured with a reproducible method, was an
important predictor of disease free survival in
osteosarcoma, and this provides a clinically rele-
vant guideline for the early detection of chemore-
sistance and the selection of definitive surgical
options.
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